Selective binding site for [3H]prostacyclin on platelets.
about
Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptorsLoss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.Lower-extremity functional electrical stimulation decreases platelet aggregation and blood coagulation in persons with chronic spinal cord injury: a pilot study.Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. Bradykinin, arginine vasopressin, prostaglandin E2 interrelationships.The prostanoids in hemostasis and thrombosis: a review.Desensitization of prostacyclin receptors in a neuronal hybrid cell line.The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid.Platelets of pseudohypoparathyroid patients: evidence that distinct receptor-cyclase coupling proteins mediate stimulation and inhibition of adenylate cyclase.Demonstration of a novel circulating anti-prostacyclin receptor antibody.Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and diseaseLow concentrations of prostaglandin E2 inhibit the prostacyclin-induced elevation of cyclic adenosine 3',5'-monophosphate in elicited populations of rat peritoneal macrophages.The role of platelets in essential hypertension.The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase.Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.Induction of prostacyclin receptor expression in human erythroleukemia cells.The effect of low-density lipoproteins on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets.Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors.Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.A comparative study of the prostanoid receptor profile of 9 alpha 11 beta-prostaglandin F2 and prostaglandin D2.Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.Prostaglandin-concentration-dependent desensitization of adenylate cyclase in human erythroleukaemia (HEL) cells is abolished by pertussis toxin and enhanced by induction by dimethyl sulphoxide.Classification of prostaglandin receptors based on coupling to signal transduction systemsAntagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.Expression of Adhesion Molecules on the Surface of Activated Platelets is Diminished by PGI(2)-analogues and an NO (EDRF)-Donor: A Comparison Between Platelets of Healthy and Diabetic Subjects.
P2860
Q28354162-5225871B-FF97-4711-A349-825794BBC89CQ33613498-B66B7425-F885-4F01-8D8F-6EEF0B20FDDEQ33848336-C1D17244-F4C7-4B28-991B-7DF61E273B51Q34611039-31662D3D-8BC8-43E7-8428-F900EC668ED6Q35863726-65ED5654-44AF-4C93-93A3-9FDCE18513FFQ36097438-5BC6D247-60C4-45B2-B336-66FBBA6D865BQ36128056-47BD008A-B720-42AE-9BDA-10579B5E285AQ36302861-A4399000-6653-4879-AE17-6F7DB7B508ADQ36559998-D06FE5F4-1489-4DF5-AD0D-7C0BBE17DE5DQ37040969-19F09475-D2A9-4E98-A7A2-54F94F8C09C8Q37212217-C517651E-8D98-4018-BCE8-716E85971DBEQ39927213-7B831071-48B0-454B-9D93-089DC6DE9468Q40381228-EA7648A6-A2A3-48FB-8DCE-234605921B06Q41808156-C4110204-6A4D-4F06-8D52-3911B35F2F74Q41846624-C5A4D605-FF45-47EA-94E9-C6D5D8EF4218Q41891625-94EA68E5-6AAA-49E2-8E85-CB50794534D4Q41902699-1961A338-FE4F-4A88-8247-7F741A65D491Q42126640-02745DBA-D903-496E-9115-964517255FA5Q42177241-C321EDEC-C0B3-41AD-9F5D-B4497B2A49ADQ42568879-1F224C73-48A7-4EBD-A6DF-7209F4BB63DBQ42711256-FEB5EC97-5AB7-4166-95BC-1ED742B35B51Q42715163-3910F274-FBCB-4E8E-8120-1E83441CFF9FQ42792351-A1B286E4-4755-49CA-AB6B-932C783AEC83Q42804177-E542DE76-3265-4CA9-A67C-F9894DF967BCQ42848237-113F658E-D3AB-42E6-843B-D3DCE64DBC02Q42848383-36CBB844-A385-4720-8D4F-FFC61B25AD1CQ54217085-C8EAE942-EF9F-452D-8238-23E44E4EC503
P2860
Selective binding site for [3H]prostacyclin on platelets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1979
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Selective binding site for [3H]prostacyclin on platelets.
@en
Selective binding site for [3H]prostacyclin on platelets.
@nl
type
label
Selective binding site for [3H]prostacyclin on platelets.
@en
Selective binding site for [3H]prostacyclin on platelets.
@nl
prefLabel
Selective binding site for [3H]prostacyclin on platelets.
@en
Selective binding site for [3H]prostacyclin on platelets.
@nl
P2093
P2860
P356
P1476
Selective binding site for [3H]prostacyclin on platelets.
@en
P2093
P2860
P304
P356
10.1172/JCI109292
P407
P577
1979-02-01T00:00:00Z